Noor Ul Ain Rehman
Fri, January 2, 2026 astatine 8:44 AM CST 2 min read
Avantor, Inc. (NYSE:AVTR) was besides downgraded to Neutral from Buy by BofA connected December 15, with the steadfast bringing the terms people down to $13 from $14. It told investors that 2026 is expected to beryllium the 3rd consecutive twelvemonth wherever markets are expected to normalize, with Life Science Tools headwinds fading. However, it besides believes that “a steadfast magnitude of caution is warranted,” stating that the biggest upside hazard for Tools/CRO markets would beryllium a instrumentality to spending by Biopharma. The steadfast frankincense favors companies with a comparatively higher R&D exposure, and believes that immoderate setbacks oregon misses successful the abstraction “will beryllium harshly punished.”
Avantor, Inc. (NYSE:AVTR) is simply a beingness sciences tools institution that provides mission-critical services and products to the precocious exertion and beingness sciences industries. The company’s portfolio includes acquisition and government, biopharma, healthcare, and applied materials and precocious technologies industries.
While we admit the imaginable of AVTR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

1 week ago
6




English (CA) ·
English (US) ·
Spanish (MX) ·